Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Sabina Kaczanowska"'
Autor:
Yuji Zhang, Sabina Kaczanowska, Cruz Velasco Gonzales, Jackline Joy Martín Lasola, Eduardo Davila, Kenisha Younger, Ann Mary Joseph, Jitao Guo, Alexander K Tsai
Publikováno v:
Cancer Research. 77:7049-7058
T cell–based immunotherapies are a promising approach for patients with advanced cancers. However, various obstacles limit T-cell efficacy, including suboptimal T-cell receptor (TCR) activation and an immunosuppressive tumor environment. Here, we d
Autor:
Sabina Kaczanowska, Eduardo Davila
Toll-like receptor (TLR) agonists are potent immunostimulatory agents that have demonstrated great potential for cancer immunotherapy. We have genetically-engineered tumor-specific T cells to deliver and secrete the TLR5 ligand (TLR5L) flagellin to t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1fc692b858b93301b7d80c074cef5a5e
https://europepmc.org/articles/PMC4839377/
https://europepmc.org/articles/PMC4839377/
Autor:
Kenisha Younger, Alexnder Tsai, Sabina Kaczanowska, Augusto C. Ochoa, Degui Geng, Eduardo Davila, Aaron P. Rapoport, Suzanne Ostrand-Rosenberg
The tumor microenvironment counters antitumor T-cell responses, in part, by blunting their activation and infiltration. Ligands that engage Toll-like receptors (TLR) on T cells and antigen-presenting cells can act as potent immune adjuvants. In this
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ed9d304ac112bfa655a8110ee89c41be
https://europepmc.org/articles/PMC4433615/
https://europepmc.org/articles/PMC4433615/
Publikováno v:
Journal of leukocyte biology. 93(6)
Review on the ability of different TLR agonists to orchestrate antitumor immune responses, or promote tumor growth, underscoring the impact of choosing among TLR agonists when applying these therapies in the clinic. Various TLR agonists are currently